The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Breakthrough Therapy status for rilzabrutinib in wAIHA addresses the lack of approved treatments for this rare and life-threatening condition.

HealthDay News — The US Food and Drug Administration (FDA) will now allow food labels to claim products have “no artificial colors” as long as they avoid petroleum-based dyes.

Decrease in male-to-female ratio seen with increasing age at diagnosis and by calendar period for those aged older than 10 years ...

Fewer interval cancers that were invasive, T2+, or non-luminal A were found in group with AI-supported mammography versus standard double reading ...

HealthDay News — For early-morning shift workers with shift work disorder (SWD), treatment with solriamfetol significantly improves sleepiness, according to a study published in the February issue of ...

Another major medical group says most gender-related surgeries for minors in the US should be postponed until adulthood. The American Medical Association (AMA) said Wednesday that surgical ...

If approved, marstacimab would be the first non-factor prophylactic treatment indicated for pediatric patients aged 6 to 11 years with hemophilia B.

Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.

Combo treatment aims to be latest to enter the weight loss space; Amgen refuses to remove drug from market despite FDA request; Novo Nordisk threatens legal action against Hims & Hers; an oral film ...

Review finds no evidence supporting CDC changes to newborn hepatitis B vaccine guidelines; universal birth dose remains the safest strategy.

Residual lung abnormalities were consistent with elevated epithelial injury biomarkers, profibrotic signaling.